Key statistics dashboard for Tivic Health Systems, Inc. (TIVC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services.
Stock Data
| Price | $0.26 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.04 |
| Price / Book | 0.07 |
| P/S | -1.79 |
| P/FCF | -0.02 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 516.03% |
| EBIT Margin | 10626.92% |
| EBITDA Margin | 10508.97% |
| Operating Margin | 10587.18% |
| Net Margin | 12019.23% |
Financial Health
| Current Ratio | 1.11 |
| Quick Ratio | 0.86 |
| Cash Ratio | 0.69 |
| Debt / Equity | 0.84 |
| Debt / Assets | 30.86% |
| Interest Coverage | -12.56 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.66 |
Per-Share Data
| Revenue per share | -0.05 |
| Book Value per share | 3.52 |
| Cash per share | 0.62 |
| FCF per share | -4.33 |
| Tangible Book Value per share | 2.49 |
| Dividend per share | 0.00 |
Related companies: BBLG · BJDX · CNTX · HSCS · MRAI · NUWE · PETV
Explore sector: Healthcare · Medical - Specialties
More sections of TIVC: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks